Drug Profile
Research programme: bacteriophage therapeutics - Armata Pharmaceuticals/Leicester & Glasgow Universities
Alternative Names: AB CD01; AmpliPhage-004Latest Information Update: 27 Mar 2023
Price :
$50
*
At a glance
- Originator AmpliPhi Biosciences Corporation; University of Glasgow; University of Leicester
- Developer Armata Pharmaceuticals; University of Glasgow; University of Leicester
- Class Antibacterials; Bacteriophages
- Mechanism of Action Bacterial DNA modulators; Bacterial RNA modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Clostridium difficile infections
Most Recent Events
- 27 Mar 2023 Discontinued - Preclinical for Clostridium difficile infections (Prevention) in United Kingdom (unspecified route)
- 27 Mar 2023 Discontinued - Preclinical for Clostridium difficile infections in United Kingdom (unspecified route)
- 28 Oct 2020 No recent reports of development identified for preclinical development in Clostridium-difficile-infections in United Kingdom